← SynDRA
THIOTEPA
SynDRA canonical compound SYN0001342 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP3A4 |
|---|
| Mechanism of action | Cytochrome P450 inhibitor |
|---|
| Indication | bladder cancer | breast cancer | ovarian cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- Cytochrome P450 inhibitor
- CYP2B6 INHIBITOR
Drug classes
- Alkylating Activity
- Alkylating Drug
- Alkylating Agents
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Immunologic Factors
- Immunosuppressive Agents
- Myeloablative Agonists
- Noxae
ATC classes
Cross-references
Synonyms
- thio-tepa
- triethylenethiophosphortriamide
- oncotepa
- phosphorothioic acid triethylenetriamide
- tespamin
- tespamine
- thiophosphamide
- tepadina
- Tiotepa
- Tepylute
- NSC-6396
- Tepadina
- Thioplex
- Thiotepa riemser
- THIO-TEPA
- Triethylenethiophosphoramide
- Thiophosphamide
- Tiofosyl
- Tiofosfamid
- Thiofozil
- Tiofozil
- Tespamin
- Oncotepa
- Tespamine
- Girostan
- Thiotef
- Stepa
- TIO TEF
- Thio-Tep
- Oncotiotepa
- Tifosyl
- Oncothio-tepa
- TESPA
- TSPA
- Thio-tepa S
- Ledertepa
- Thiotriethylenephosphoramide
- N,N',N''-Triethylenethiophosphoramide
Reported adverse events
- Dysuria
- Dizziness
- Nausea
- Delirium
- Infection
- Renal failure
- Hypersensitivity
- Skin depigmentation
- Conjunctivitis
- Dermatitis
- Hepatomegaly
- Rash
Look up THIOTEPA in the interactive SynDRA portal →